 | • レポートコード：MRC2211A009 • 出版社/出版日：Persistence Market Research / 2022年9月 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：バイオ |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、バイオシミラーの世界市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、需要分析・予測、価格分析、市場背景、製品種類別（リコンビナントグリコシル化タンパク質、組換え非グリコシル化タンパク質）分析、用途別（ヘマトロジー、成長ホルモン欠乏症、腫瘍、自己免疫性糖尿病、疾患）分析、流通チャネル別（病院薬局、オンライン薬局、小売薬局）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア太平洋、中東/アフリカ）分析、仮定、調査手法などを整理しております。本書では、Pfizer Inc.、Sandoz International GMBH、Eli Lily＆Company、Hospira Inc.、Amgen, Inc.、Biocon Ltd.、Actavis, Inc.、Cipla Ltd.、Teva Pharmaceutical Industries, Ltd.、Dr. Reddy’s Laboratories Ltd.、Celltrion, Inc.、Stada Arzeimittel Ag、Mylan, Inc.、Wockhardt Ltd.などの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・需要分析・予測 ・価格分析 ・市場背景 ・世界のバイオシミラー市場規模：製品種類別 - リコンビナントグリコシル化タンパク質の市場規模 - 組換え非グリコシル化タンパク質の市場規模 ・世界のバイオシミラー市場規模：用途別 - ヘマトロジーにおける市場規模 - 成長ホルモン欠乏症における市場規模 - 腫瘍における市場規模 - 自己免疫性糖尿病における市場規模 - 疾患における市場規模 ・世界のバイオシミラー市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界のバイオシミラー市場規模：地域別 - 北米のバイオシミラー市場規模 - 中南米のバイオシミラー市場規模 - ヨーロッパのバイオシミラー市場規模 - 東アジアのバイオシミラー市場規模 - 南アジア太平洋のバイオシミラー市場規模 - 中東/アフリカのバイオシミラー市場規模 ・仮定 ・調査手法 |
Biosimilars Market: Report Scope
The latest market report by Persistence Market Research on the global biosimilars market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides detailed assessment of key market dynamics, and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.
The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with biosimilars. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.
This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on the future trends in the market. Furthermore, new and emerging players in the global biosimilars market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.
The study is relevant for manufacturers, suppliers, distributors, and investors in the biosimilars market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.
Key Market Segments
Persistence Market Research’s report on the global biosimilars market offers information divided into four segments – product type, application, distribution channel, and region.
Product Type
Recombinant Glycosylated Proteins
Recombinant Non-Glycosylated Proteins
Application
Hematology
Growth Hormone Deficiency
Oncology
Diabetes Autoimmune
Disease
Others
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa
Key Questions Answered in Study
Which region will hold the highest market share over the forecast period?
Which region is experiencing the highest growth (CAGR)?
Which factors are impacting the global biosimilars industry?
What are the global trends impacting the market?
What strategies must emerge players adopt to capture opportunities in various regions in the market?
What is the structure of the global biosimilars market?
Research Methodology
Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global biosimilars market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.
A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.
This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions – North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.
Our main sources of research include:
Primary Research
Secondary Research
Trade Research
Social Media Research
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. Strategic Promotional Strategies
5. Global Biosimilars Market Demand Analysis 2017–2021 and Forecast, 2022–2032
5.1. Historical Market Volume (Tons) Analysis, 2017–2021
5.2. Current and Future Market Volume (Tons) Projections, 2022–2032
5.3. Y-o-Y Growth Trend Analysis
6. Global Biosimilars Market – Pricing Analysis
6.1. Regional Pricing Analysis By Product Type
6.2. Global Average Pricing Analysis Benchmark
7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Industry Value Added Overview
8.1.3. Global Infrastructure Investment Overview
8.1.4. Global Construction Spending Analysis
8.1.5. Other Macro Economic Factors
8.2. Forecast Factors – Relevance & Impact
8.2.1. Top Companies Historical Growth
8.2.2. GDP Growth forecast
8.2.3. Construction Industry forecast
8.2.4. Distribution Channel Growth Outlook
8.2.5. Collaboration Activities
8.3. Value Chain
8.3.1. Raw Material Suppliers
8.3.2. List of Manufacturers
8.3.3. List of Distributors
8.4. COVID-19 Crisis – Impact Assessment
8.4.1. Current Statistics
8.4.2. Short-Mid-Long Term Outlook
8.4.3. Likely Rebound
8.5. Market Dynamics
8.5.1. Drivers
8.5.2. Restraints
8.5.3. Opportunity Analysis
8.5.4. Trends
9. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Product Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021
9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product Type 2022–2032
9.3.1. Recombinant Glycosylated Proteins
9.3.2. Recombinant Non-Glycosylated Proteins
9.4. Market Attractiveness Analysis by Product Type
10. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021
10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032
10.3.1. Hematology
10.3.2. Growth Hormone Deficiency
10.3.3. Oncology
10.3.4. Diabetes Autoimmune
10.3.5. Disease
10.3.6. Others
10.4. Market Attractiveness Analysis By Application
11. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021
11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia and Pacific
12.3.6. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.2. By Type
13.4.3. By Application
13.4.4. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Type
13.5.3. By Application
13.5.4. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants – Intensity Mapping
13.8. Drivers and Restraints – Impact Analysis
14. Latin America Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Type
14.4.3. By Application
14.4.4. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Type
14.5.3. By Application
14.5.4. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants – Intensity Mapping
14.8. Drivers and Restraints – Impact Analysis
15. Europe Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. U.K.
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Rest of Europe
15.4.2. By Type
15.4.3. By Application
15.4.4. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Type
15.5.3. By Application
15.5.4. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants – Intensity Mapping
15.8. Drivers and Restraints – Impact Analysis
16. South Asia and Pacific Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
16.4.1. By Country
16.4.1.1. India
16.4.1.2. ASEAN
16.4.1.3. Oceania
16.4.1.4. Rest of South Asia & Pacific
16.4.2. By Type
16.4.3. By Application
16.4.4. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Type
16.5.3. By Application
16.5.4. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants – Intensity Mapping
16.8. Drivers and Restraints – Impact Analysis
17. East Asia Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
17.4.1. By Country
17.4.1.1. China
17.4.1.2. Japan
17.4.1.3. South Korea
17.4.2. By Type
17.4.3. By Application
17.4.4. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Type
17.5.3. By Application
17.5.4. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants – Intensity Mapping
17.8. Drivers and Restraints – Impact Analysis
18. Middle East and Africa Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
18.4.1. By Country
18.4.1.1. GCC Countries
18.4.1.2. Turkey
18.4.1.3. Northern Africa
18.4.1.4. South Africa
18.4.1.5. Rest of Middle East and Africa
18.4.2. By Type
18.4.3. By Application
18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Type
18.5.3. By Application
18.5.4. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants – Intensity Mapping
18.8. Drivers and Restraints – Impact Analysis
19. Emerging Countries Biosimilars Market Analysis
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Biosimilars Market Analysis
19.2.1. By Type
19.2.2. By Application
19.2.3. By Distribution Channel
19.3. Canada Biosimilars Market Analysis
19.3.1. By Type
19.3.2. By Application
19.3.3. By Distribution Channel
19.4. Mexico Biosimilars Market Analysis
19.4.1. By Type
19.4.2. By Application
19.4.3. By Distribution Channel
19.5. Brazil Biosimilars Market Analysis
19.5.1. By Type
19.5.2. By Application
19.5.3. By Distribution Channel
19.6. Germany Biosimilars Market Analysis
19.6.1. By Type
19.6.2. By Application
19.6.3. By Distribution Channel
19.7. Italy Biosimilars Market Analysis
19.7.1. By Type
19.7.2. By Application
19.7.3. By Distribution Channel
19.8. France Biosimilars Market Analysis
19.8.1. By Type
19.8.2. By Application
19.8.3. By Distribution Channel
19.9. U.K. Biosimilars Market Analysis
19.9.1. By Type
19.9.2. By Application
19.9.3. By Distribution Channel
19.10. Spain Biosimilars Market Analysis
19.10.1. By Type
19.10.2. By Application
19.10.3. By Distribution Channel
19.11. BENELUX Biosimilars Market Analysis
19.11.1. By Type
19.11.2. By Application
19.11.3. By Distribution Channel
19.12. Russia Biosimilars Market Analysis
19.12.1. By Type
19.12.2. By Application
19.12.3. By Distribution Channel
19.13. China Biosimilars Market Analysis
19.13.1. By Type
19.13.2. By Application
19.13.3. By Distribution Channel
19.14. Japan Biosimilars Market Analysis
19.14.1. By Type
19.14.2. By Application
19.14.3. By Distribution Channel
19.15. S. Korea Biosimilars Market Analysis
19.15.1. By Type
19.15.2. By Application
19.15.3. By Distribution Channel
19.16. India Biosimilars Market Analysis
19.16.1. By Type
19.16.2. By Application
19.16.3. By Distribution Channel
19.17. ASEAN Biosimilars Market Analysis
19.17.1. By Type
19.17.2. By Application
19.17.3. By Distribution Channel
19.18. Australia and New Zealand Biosimilars Market Analysis
19.18.1. By Type
19.18.2. By Application
19.18.3. By Distribution Channel
19.19. GCC Countries Biosimilars Market Analysis
19.19.1. By Type
19.19.2. By Application
19.19.3. By Distribution Channel
19.20. Turkey Biosimilars Market Analysis
19.20.1. By Type
19.20.2. By Application
19.20.3. By Distribution Channel
19.21. Northern Africa Biosimilars Market Analysis
19.21.1. By Type
19.21.2. By Application
19.21.3. By Distribution Channel
19.22. South Africa Biosimilars Market Analysis
19.22.1. By Type
19.22.2. By Application
19.22.3. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Pfizer Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.2. Sandoz International GMBH
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.3. Eli Lily & Company
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.4. Hospira Inc.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.5. Amgen, Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.6. Biocon Ltd.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.7. Actavis, Inc.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.8. Cipla Ltd.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.9. Teva Pharmaceutical Industries, Ltd.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
21.3.10. Dr. Reddy’s Laboratories Ltd.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Strategy Overview
21.3.11. Celltrion, Inc.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Strategy Overview
21.3.12. Stada Arzeimittel Ag
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Profitability by Market Segments (Product/Channel/Region)
21.3.12.4. Sales Footprint
21.3.12.5. Strategy Overview
21.3.13. Mylan, Inc.
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Profitability by Market Segments (Product/Channel/Region)
21.3.13.4. Sales Footprint
21.3.13.5. Strategy Overview
21.3.14. Wockhardt Ltd.
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Profitability by Market Segments (Product/Channel/Region)
21.3.14.4. Sales Footprint
21.3.14.5. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Table 01: Global Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032Table 02: Global Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 03: Global Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032
Table 04: Global Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Region, 2017– 2032
Table 05: North America Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017– 2032
Table 06: North America Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032
Table 07: North America Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 08: North America Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032
Table 09: Latin America Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017– 2032
Table 10: Latin America Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032
Table 11: Latin America Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 12: Latin America Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032
Table 13: Europe Biosimilars Market Volume ('000 Units) Forecast by Country 2017– 2032
Table 14: Europe Biosimilars Market Value(US $ Mn) Forecast by Country, 2017– 2032
Table 15: Europe Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032
Table 16: Europe Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 17: Europe Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032
Table 18: South Asia & Pacific Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Country,2017– 2032
Table 19: South Asia & Pacific Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032
Table 20: South Asia & Pacific Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 21: South Asia & Pacific Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032
Table 22: East Asia Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Country, 2017– 2032
Table 23: East Asia Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032
Table 24: East Asia Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 25: East Asia Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032
Table 26: Middle East & Africa Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Country, 2017– 2032
Table 27: Middle East & Africa Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Product Type, 2017– 2032
Table 28: Middle East & Africa Biosimilars Market Volume ('000 Units) & Value (US$ Mn) Forecast by Application, 2017– 2032
Table 29: Middle East & Africa Biosimilars Market Volume ('000 Units) & Value(US$ Mn) Forecast by Distribution Channel, 2017– 2032